Collegium Pharmaceutical Inc

Company Profile

• Business description

  Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

• Contact

  100 Technology Center Drive
  StoughtonMA02072
  USA

  T: +1 781 713-3699

  E: [email protected]

  https://www.collegiumpharma.com

• Sector

  Healthcare

  Stock type

  Defensive

• Industry

  Drug Manufacturers - Specialty & Generic

  Fiscal Year End

  31 December 2025

  Employees

  197